All In Biotech

Drug Trial Radar · NCT06799065

First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer

A Phase 1/2, Open-Label, Dose-Escalation and Expansion First-In-Human Study of ATX-295, an Oral Inhibitor of the Kinesin Motor Protein KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Locally Advanced or Metastatic Solid Tumors, Including High-Grade Serous Ovarian Cancer

Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

218

Planned (sponsor's estimate)

Start

Mar 21, 2025

Primary completion

Apr 30, 2027

Study completion Aug 30, 2027

Sponsor

Lead sponsor
Accent TherapeuticsIndustry
Sponsor type
Industry
First posted
Jan 29, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this study is to identify a safe and tolerated dose of the orally administered KIF18A inhibitor ATX-295. In addition, this study will evaluate the pharmacokinetics, pharmacodynamics and preliminary antitumor activity of ATX-295 as a monotherapy and in combination with bevacizumab (or a biosimilar) in patients with locally advanced or metastatic solid tumors, including ovarian cancer and lung cancer.

Conditions

  • Advanced Solid Tumors
  • Breast Cancer Recurrent
  • Ovarian Cancer
  • High-grade Serous Ovarian Carcinoma
  • Triple Negative Breast Cancer
  • sqNSCLC
  • Squamous Non-small-cell Lung Cancer

Interventions

  • ATX-295Drug

    ATX-295 tablets will be taken orally

  • ATX-295 and bevacizumab (or biosimilar)Drug

    ATX-295 tablets will be taken orally in combination with bevacizumab (or biosimilar) administered via intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Recommended phase 2 dose (RP2D) and/or maximum tolerated dose (MTD) of ATX-295 as a monotherapy and in combination with bevacizumab (or biosimilar)Time frame: 12 months
  2. Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)Time frame: 12 months

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • University of Colorado Denver

    Aurora, Colorado · Recruiting

  • Florida Cancer Specialists

    Sarasota, Florida · Recruiting

  • Karmanos Cancer Institute

    Detroit, Michigan · Recruiting

  • Washington University

    St Louis, Missouri · Recruiting

  • University of Nebraska Medical Center

    Omaha, Nebraska · Recruiting

  • NYU Longone Health (Long Island)

    Long Island City, New York · Recruiting

  • NYU Longone Health (Manhattan)

    Manhattan, New York · Recruiting

  • SCRI Oncology Partners

    Nashville, Tennessee · Recruiting

  • MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • NEXT Oncology

    San Antonio, Texas · Recruiting

  • NEXT Virginia

    Fairfax, Virginia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.